Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.

NCT00558272 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00558272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00558272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
August 31, 2012
Enrollment
139 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

bone neoplasms, breast cancer, prostate cancer